Novartis again leads growing Turkish pharma market
This article was originally published in Scrip
Executive Summary
The Turkish pharmaceutical market delivered a good performance in 2014, growing by around 9%, although the declining lira meant market expansion remained insignificant in US dollar terms. Alimentary, antineoplastic and immunomodulatory products became best sellers, and as of the end of November 2014, Novartis led the market.